Sopharma AD (the “Company”) notifies that for August 2013 the Company realized a decrease of sales revenues of 8% compared to the same period of 2012, as a result of retained level of domestic sales and 12% decrease of export sales.
During the past eight months Sopharma AD recorded a decrease of sales revenues of 2%, including 4% increase of domestic sales and 5% decrease of export sales compared to the same period of 2012.
Sopharma AD (the “Company”) announces that on 10 September 2013 the Company received a notification for the acquisition of 11,885,951 shares, representing 9% of its capital, by Rompharm Company OOD. After the transaction the share of Rompharm Company OOD in the capital of Sopharma AD reached 13.53%.
SOPHARMA AD (the “Company”) hereby informs that from 5 September 2013 up to and including 11 September 2013 the Company bought 2300 own shares representing 0.0017 % of the share capital of the Company, to the total value of 7 516.30 BGN on the Bulgarian Stock Exchange. The average price per share was 3.27 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 215 717, representing 3.95% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 12 September 2013 up to and including 18 September 2013 the Company bought 4005 own shares representing 0.003 % of the share capital of the Company, to the total value of 13 062.13 BGN on the Bulgarian Stock Exchange. The average price per share was 3.26 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 219 722, representing 3.95% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 19 September 2013 up to and including 25 September 2013 the Company bought 14 524 own shares representing 0.011 % of the share capital of the Company, to the total value of 47 714.54 BGN on the Bulgarian Stock Exchange. The average price per share was 3.29 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 234 246, representing 3.97% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 26 September 2013 up to and including 2 October 2013 the Company bought 13 735 own shares representing 0.01 % of the share capital of the Company, to the total value of 45 237.71 BGN on the Bulgarian Stock Exchange. The average price per share was 3.29 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 247 981, representing 3.98% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for September 2013 the Company realized an increase of sales revenues of 12% compared to the same period of 2012, including 17% increase of domestic sales and 10% increase of export sales.
During the past nine months Sopharma AD recorded a decrease of sales revenues of 1%, including 6% increase of domestic sales and 3% decrease of export sales compared to the same period of 2012.
SOPHARMA AD (the “Company”) hereby informs that from 3 October 2013 up to and including 9 October 2013 the Company bought 42 014 own shares representing 0.032% of the share capital of the Company, to the total value of 136 725.01 BGN on the Bulgarian Stock Exchange. The average price per share was 3.254 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 289 995, representing 4.01% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 10 October 2013 up to and including 16 October 2013 the Company bought 7 650 own shares representing 0.0058% of the share capital of the Company, to the total value of 24 998.10 BGN on the Bulgarian Stock Exchange. The average price per share was 3.27 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 297 645, representing 4.01% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 17 October 2013 up to and including 23 October 2013 the Company bought 34 425 own shares representing 0.026% of the share capital of the Company, to the total value of 112 552.98 BGN on the Bulgarian Stock Exchange. The average price per share was 3.27 BGN.
The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 332 070, representing 4.04% of the share capital of the Company.
